Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kantone Holdings Ltd
HKEX:1059
|
HK |
|
N
|
NZ Automotive Investments Ltd
NZX:NZA
|
NZ |
|
HELMA Eigenheimbau AG
XETRA:H5E
|
DE |
|
T
|
TANSH Global Food Group Co Ltd
HKEX:3666
|
CN |
|
A
|
Anhui Fengyuan Pharmaceutical Co Ltd
SZSE:000153
|
CN |
Genfit SA
Total Liabilities
Genfit SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€181.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
29%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€292.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
8%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€187.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Total Liabilities
$248.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities
$64.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
12%
|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities
€164.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
20%
|
CAGR 10-Years
36%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Total Liabilities?
Total Liabilities
181.6m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Total Liabilities amounts to 181.6m EUR.
What is Genfit SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
29%
Over the last year, the Total Liabilities growth was 121%. The average annual Total Liabilities growth rates for Genfit SA have been 14% over the past three years , -3% over the past five years , and 29% over the past ten years .
